Parkinson's disease (PD) is the second most common form of neurodegenerative disease and afflicts more than ten million ...

Roughly one in nine Americans aged 65 and older is exposed to a prescription drug combination flagged as a major drug-drug ...

Silevertinib, Black Diamond Therapeutics' lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR. Read why ...

Amyotrophic lateral sclerosis (ALS) received widespread attention in the summer of 2014 thanks to the Ice Bucket Challenge. Millions of people participated, drenching themselves in ice-cold water to ...

CNS metastases represent one of the most devastating complications of non-small-cell lung cancer (NSCLC), affecting up to 50% of patients during their ...

Axsome Therapeutics(NASDAQ: AXSM) has been going through a particularly significant growth phase in recent years, launching ...

Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026Affirms 2026 guidance on key milestones Reports ...

Investment firm Deerfield Management is the latest to find a gem in China, which has been rising as a source of biotech innovation over the past few years. Investment firm Deerfield Management has ...

Fasting blood tests measuring GLP-1 and GIP levels may predict obesity treatment response to semaglutide and tirzepatide, ...

Insilico Medicine will partner with SK Biopharmaceuticals to discover new artificial intelligence (AI)-based drug candidates for disorders affecting the neuroimmune area of the central nervous system ...

Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studiesExtends NeOnc’s UAE footprint beyond ...

Several ASX healthcare companies are tackling neurodegenerative diseases where effective treatments remain limited.